Bausch & Lomb (BLCO) EBITDA Margin (2021 - 2026)
Bausch & Lomb's (BLCO) quarterly EBITDA Margin came in at 5.95% in Q2 2026, up 681.0% on a YoY basis from 0.76% in Q2 2025, and up 124.45% quarter-over-quarter from 2.65% in Q1 2026.
Powered by 
Analysis
Bausch & Lomb (BLCO) EBITDA Margin (2021 - 2026) Analysis & Trends
Bausch & Lomb (BLCO) has reported EBITDA Margin for 6 consecutive years, with 5.95% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 681.0% year-over-year to 5.95%; the trailing twelve-month figure through Jun 2026 stood at 6.07% (up 533.0% YoY), and the FY2025 full-year result was 2.22%, down 117.0% from the prior year.
- EBITDA Margin rose to 5.95% in Q2 2026 per BLCO's latest filing, from 2.65% in the prior quarter.
- Across five years, EBITDA Margin topped out at 7.97% in Q4 2025 and bottomed at 7.3% in Q1 2025.
- Historically, EBITDA Margin has averaged 3.5% across 5 years, with a median of 4.17% in 2023.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 785 bps in 2025, then jumped 995 bps in 2026.
- Over 5 years, EBITDA Margin stood at 5.12% in 2022, then retreated by 18 bps to 4.18% in 2023, then jumped by 63 bps to 6.8% in 2024, then gained by 17 bps to 7.97% in 2025, then fell by 25 bps to 5.95% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.95%, 2.65%, and 7.97% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 19.15% |
| 10 | Bausch & Lomb | 6.28 Bn | 5.90 Bn | 867.00 Mn | 5.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.95% |
| Mar 31, 2026 | 2.65% |
| Dec 31, 2025 | 7.97% |
| Sep 30, 2025 | 7.42% |
| Jun 30, 2025 | -0.86% |
| Mar 31, 2025 | -7.30% |
| Dec 31, 2024 | 6.80% |
| Sep 30, 2024 | 3.60% |
| Jun 30, 2024 | 2.14% |
| Mar 31, 2024 | 0.55% |
| Dec 31, 2023 | 4.18% |
| Sep 30, 2023 | 3.97% |
| Jun 30, 2023 | 4.15% |
| Mar 31, 2023 | -0.21% |
| Dec 31, 2022 | 5.12% |
| Sep 30, 2022 | 4.88% |
| Jun 30, 2022 | 5.95% |
| Mar 31, 2022 | 6.07% |
| Dec 31, 2021 | 9.19% |
| Sep 30, 2021 | 9.91% |